NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development

   NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business

Mr. Wiley Also to Direct Commercialization Strategy and Activities for

PR Newswire

AMES, Iowa, Jan. 3, 2013

AMES, Iowa, Jan.3, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ:
NLNK), a biopharmaceutical company focused on discovering, developing and
commercializing novel immunotherapeutic products to improve treatment options
for cancer patients, today announced the appointment of Mr. Brian Wiley as
Vice President of Business Development. In addition to business development
responsibilities, Mr. Wiley will lead the commercialization strategy and
pre-commercial activities for NewLink's HyperAcute® Pancreas Immunotherapy,

"Brian brings extensive and varied pharmaceutical experience to our management
team, most recently with key roles in both the sale of Gloucester
Pharmaceuticals to Celgene Corporation and the purchase of Abraxis Health by
Celgene," commented Dr. Charles Link, Chief Executive Officer of NewLink. Dr.
Link added, "In addition to his business development experience, Brian has had
key responsibilities in the launch, marketing and sales of a variety of
oncology products at both major pharmaceutical companies and smaller biotech
companies. We are excited to have Brian join our team."

Mr. Wiley has over 20 years of pharmaceutical experience, with 16 of those
years in oncology markets. He has had management responsibilities at Celgene
Corporation, Gloucester Pharmaceuticals, Millennium Pharmaceuticals (currently
Takeda) and Aventis Pharmaceuticals (currently Sanofi-Aventis). Mr. Wiley has
also served as an independent consultant to numerous companies in the oncology
market. His responsibilities have included business development, commercial
strategy, marketing, reimbursement, national accounts, sales and sales

About algenpantucel-L

NewLink's algenpantucel-L is an "off-the-shelf" immunotherapy product
candidate consisting of two allogeneic pancreatic cancer cell lines. These
cell lines were chosen to provide a broad coverage of pancreatic cancer
antigens and were then modified to express alpha-gal on the cell surface to
increase immunogenicity. Each modified cell line is grown in large-scale
culture, harvested, packaged and irradiated. Approximately 150 million cells
of each HyperAcute Pancreas cell line are given by intradermal injection with
each treatment.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on
discovering, developing and commercializing novel immunotherapeutic products
to improve treatment options for cancer patients. NewLink's portfolio includes
biologic and small-molecule immunotherapy product candidates intended to treat
a wide range of oncology indications. NewLink's product candidates are
designed to harness multiple components of the immune system to combat cancer
without significant incremental toxicity, either as a monotherapy or in
combination with other treatment regimens. NewLink's lead product candidate,
algenpantucel-L (HyperAcute Pancreas) is being studied in a Phase 3 clinical
trial in surgically resected pancreatic cancer patients (under a Special
Protocol Assessment with the U.S. FDA) as well as in a separate study in
locally advanced pancreatic cancer patients. NewLink has recently launched an
adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute
Lung) in patients with non-small cell lung cancer. NewLink is developing
indoximod (d-1-methyltryptophan, or D-1MT), a small-molecule, orally
bioavailable product candidate from NewLink's proprietary indoleamine-(2,
3)-dioxygenase, or IDO, pathway inhibitor technology. NewLink is studying
indoximod in various chemotherapy and immunotherapy combination studies
independently and in collaboration with the National Cancer Institute. For
more information please visit Patient information is
available at

Safe Harbor Statement

This press release contains forward-looking statements of NewLink that involve
substantial risks and uncertainties. All statements, other than statements of
historical facts, contained in this press release are forward-looking
statements, within the meaning of The Private Securities Litigation Reform Act
of 1995. The words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan,""target," "potential," "will,""could," "should," "seek," or the
negative of these terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. These forward-looking statements include,
among others, statements about the prospects of algenpantucel-L and any other
statements other than statements of historical fact. Actual results or events
could differ materially from the plans, intentions and expectations disclosed
in the forward-looking statements that NewLink makes due to a number of
important factors, including those risks discussed in "Risk Factors" and
elsewhere in NewLink's Annual Report on Form 10-K for the period ended
December 31, 2011, in its Quarterly Report on Form 10-Q for the period ended
September 30, 2012, and in its other filings with the Securities and Exchange
Commission. The forward-looking statements in this press release represent
NewLink's views as of the date of this press release. NewLink anticipates that
subsequent events and developments will cause its views to change. However,
while it may elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as representing
NewLink's views as of any date subsequent to the date of this press release.

Gordon Link
Chief Financial Officer
NewLink Genetics

SOURCE NewLink Genetics Corporation

Press spacebar to pause and continue. Press esc to stop.